Doxycycline - OncoSynergy

Drug Profile

Doxycycline - OncoSynergy

Alternative Names: NX-101; OS-342

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator NexGenix Pharmaceuticals
  • Class Antibacterials; Antimalarials; Small molecules; Tetracyclines
  • Mechanism of Action Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Neurofibromatoses

Most Recent Events

  • 30 May 2013 Biomarkers information updated
  • 17 Jul 2007 Phase-II clinical trials in Neurofibromatosis in Mexico (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top